Moderna, Inc. (MRNA): Price and Financial Metrics
MRNA Stock Summary
- MRNA has a higher market value than 96.34% of US stocks; more precisely, its current market capitalization is $67,760,944,149.
- With a price/sales ratio of 84.34, Moderna Inc has a higher such ratio than 96.03% of stocks in our set.
- Revenue growth over the past 12 months for Moderna Inc comes in at 1,234.34%, a number that bests 99.36% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Moderna Inc are INCY, GMAB, VIR, RVMD, and MU.
- Visit MRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.modernatx.com.
MRNA Stock Price Chart Interactive Chart >
MRNA Price/Volume Stats
| Current price | $174.65 | 52-week high | $189.26 |
| Prev. close | $168.10 | 52-week low | $45.01 |
| Day low | $168.35 | Volume | 6,158,191 |
| Day high | $174.94 | Avg. volume | 11,702,379 |
| 50-day MA | $147.67 | Dividend yield | N/A |
| 200-day MA | $109.43 | Market Cap | 69.95B |
Moderna, Inc. (MRNA) Company Bio
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA
Latest MRNA News From Around the Web
Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
Pressure mounting on Biden administration to waive COVID-19 vaccine patentsAs poorer countries struggle to vaccinate their citizens, calls are growing for the Biden administration to waive COVID-19 patents in a bid to increase vaccine production.Last week, more than 170 former world leaders and Nobel Laureates signed an open letter to President Biden urging him to sign a temporary waiver... |
OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing TodayOCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate. |
The 7 Best-Performing ETFs Money Can Buy In 2021Here're seven of the most popular ETFs so far in 2021 |
Most BJP-ruled states announce free jabs for allTwo days after the Centre announced vaccination for all above the age of 18 years from May 1, state governments are busy finalising the modalities to place their orders. While most BJP-ruled states have announced free vaccinations, the worst-affected states like Maharashtra and Delhi are yet to take a call on pricing as well as orders for the vaccine drive.“We have not got any official communication from the Centre on this. We might get this communication by tomorrow and then formulate a plan,” DN Patil, Maharashtra Immunisation officer told ET. Maharashtra has sought the Centre’s nod to import vaccines like Sputnik, Moderna and Pfizer to vaccinate nearly 10 crore of its 12 crore population.Uttar Pradesh health minister Jai Pratap Singh told ET that more clarity needs to emerge on the p... |
Why Moderna Stock Jumped TodayShares of Moderna (NASDAQ: MRNA) were jumping 7.4% higher as of 3:42 p.m. EDT on Wednesday. The gain came after the company announced that it won a new deal to supply its COVID-19 vaccine to Israel for 2022. Moderna didn't reveal how many doses are included in its latest agreement with Israel. |
MRNA Price Returns
| 1-mo | 32.70% |
| 3-mo | 33.30% |
| 6-mo | 147.63% |
| 1-year | 268.15% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 67.18% |
| 2020 | 434.10% |
| 2019 | 28.09% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...